Abstract
Total plasma homocysteine was analysed in 64 cases of retinal vein occlusion (RVO) of which 24 cases of central retinal vein occlusion (CRVO) and 40 cases of branch retinal vein occlusion (BRVO) and compared with 45 age and sex matched control. Homocysteine was significantly increased in RVO cases in respect to control (P < 0.001). Analysis also revealed that prevalence of rise of plasma homocysteine was more in cases of CRVO (OR = 13) than that of BRVO (OR = 5.03).
Similar content being viewed by others
References
Kanski JJ. Clinical ophthalmology: a systematic approach. 6th ed. Philadelphia: Butterworth-Heinemann; 2007. p. 584–5.
Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb. 2002;32:308–11.
Lahey JM, Kerarney JJ, Tunc M. Hypercoagulable states and central retinal vein occlusion. Curr Opin Pulm Med. 2003;9(5):385–92.
Boyd S, Owens D, Gin T, Bunce K, Sherafat H, Perry D, et al. Plasma homocysteine methylene tetrahydrofolate reductase C677T and factor II G2010A polymorphism, factor VIII and VWF in central retinal vein occlusion. Br J Ophthalmol. 2001;85:1313–5.
Genser D, Prachar H, Hauer R, Halbmayer M, Mlczoch J, Elmadfa I. Homocysteine, folate and vitamin B12 in patients with coronary heart disease. Ann Nutr Metab. 2006;50(5):413–9.
Pianka P, Almog Y, Man O, Goldstein M, Sela BA, Loewenstein A. Hyperhomocysteinemia in patients with nonarteric anterior ischemic optic neuropathy: central retinal artery occlusion and central retinal vein occlusion. Ophthalmology. 2000;107:1588–92.
Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF. Hyperhomocysteine in retinal artery and retinal vein occlusion. Am J Ophthalmol. 1993;115:162–7.
Brown BA, Marx JL, Ward TP, Hollifield RD, Dick JS, Brozetti JJ, et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology. 2002;109(2):287–90.
Lentz R. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost. 2005;3:1646–54.
Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab. 2005;6(1):27–54.
Postea O, Krotz F, Henger A, Keller C, Weiss N. Stereospecific and redox-sensitive increase in monocyte adhesion to endothelial cells by homocysteine. Arterioscler Thromb Vasc Biol. 2006;26(3):508–13.
Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr. 2006;136(Suppl 6):1741S–9S.
Jacobsen DW, Catanescu O, Barbato JC. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis. Clin Chem Lab Med. 2005;43(10):1076–83.
Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr. 2006;136:1726S–30S.
Lattanzio R, Sampirtro F, Ramonia A, Fattorini A, Brancato R. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina. 2006;26(1):65–70.
Finkelstein JD. Inborn errors of sulfur-containing amino acid metabolism. J Nutr. 2006;136(suppl 6):1750S–4S.
Pinna A, Carru C, Zinellu A, Dore S, Deiana L, Carta F. Plasma homocysteine and cysteine levels in retinal vein occlusion. Invest Ophthalmol Vis Sci. 2006;47(9):4067–71.
Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal emboli the Blue Mountains eye study. Am J Ophthalmol. 2006;142(2):322–4.
Chau B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal vein occlusion: population based study. Am J Ophthalmol. 2005;139(1):181–2.
Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH, et al. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993;39:1764–79.
Di Crecchio L, Parodi MB, Sanguinetti G, Iacono P, Ravalico G. Hyper homocysteinemia and the methylenetetrahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology. 2004;111:940–5.
Gao W, Wang YS, Zhang P, Wang HY. Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population. Graefes Arch Clin Exp Ophthalmol. 2006;244(10):1246–9.
Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis?—a meta-analysis of thrombophilic factors. Thromb Haemost. 2005;93(6):1021–6.
Cahil MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B12, and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003;136(6):1136–50.
Dayal S, Devlin AM, McCaw RB, Liu ML, Arning E, Bottiglieri T, et al. Cerebral vascular dysfunction in methionine synthase-deficient mice. Circulation. 2005;112(5):737–44.
Poloschek CM, Fowler B, Unsold R, Lorenz B. Disturbed visual system function in methionine synthase deficiency. Graefes Arch Clin Exp Ophthalmol. 2005;243(5):497–500.
Kerkeni M, Tnani M, Chuniaud L, Miled A, Maaroufi K, Trivin F. Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC Cells: evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone. Mol Cell Biochem. 2006;291(1–2):119–26.
Undas A, Brozek J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost. 2005;94(5):907–15.
Conflict of interest
Nil.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lahiri, K.D., Dutta, J., Datta, H. et al. Hyperhomocysteinemia, as an Independent Risk Factor for Retinal Venous Occlusion in an Indian Population. Ind J Clin Biochem 28, 61–64 (2013). https://doi.org/10.1007/s12291-012-0238-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-012-0238-3